We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Recommends Alexion’s Strensiq to Treat Rare Bone Disease
EMA Recommends Alexion’s Strensiq to Treat Rare Bone Disease
The European Medicines Agency Friday recommended under exceptional circumstances Alexion Pharmaceutical’s Strensiq for the long-term treatment of hypophosphatasia, a rare metabolic disorder that weakens bones.